

March 2009

CURRICULUM VITAE

Alexandra S. Potter Ph.D.

Clinical Neuroscience Research Unit
Department of Psychiatry
University of Vermont College of Medicine
1 South Prospect Street
Burlington, VT 05401

Voice: (802) 847-6955

Email: Alexandra.Potter@uvm.edu

EDUCATION

Undergraduate

1986-1990

University of Vermont, Burlington, Vermont,
Bachelor of Arts (BA) in Psychology, cum laude

Graduate

1996 – 2003

University of Vermont, Department of Psychology,
Ph.D. in Clinical Psychology

Pre-Doctoral Internship

2001

Behavior Therapy and Psychotherapy Center, Department of
Psychology, University of Vermont

DISSERTATION

The Effects of Acute Nicotine Administration in Adolescents
with Attention-Deficit/Hyperactivity Disorder (ADHD).
Dissertation Thesis Advisor: Paul Newhouse, MD

PROFESSIONAL LICENSURE

State of Vermont
Licensed Clinical Psychologist Doctorate
License # 0900

ACADEMIC APPOINTMENTS AND PROFESSIONAL POSITIONS

Sept. 1991 – Sept. 1996 Research Analyst, Clinical Neuroscience Research Unit,
University of Vermont College of Medicine

May 2003 – April 2005 Post Doctoral Associate, Department of Psychiatry,
University of Vermont College of Medicine

May 2003 – Current Clinical Psychologist and Clinical Supervisor
Behavior Therapy and Psychotherapy Center
Department of Psychology, University of Vermont

June 2003 – Current Adjunct Faculty Member, Instructor, Program in Community
Mental Health, Southern New Hampshire University

April 2005 – Current Assistant Professor, Department of Psychiatry,
University of Vermont College of Medicine

January 2008– Current Clinical Assistant Professor, Department of Psychology,
University of Vermont

TRAINING INTERNSHIPS

- 1996 Clinical Neuroscience Research Unit, Department of Psychiatry,
University of Vermont. (20 hours/week).
- 1997 Vermont Interdisciplinary Leadership and Education for Healthcare
Professionals, Department of Communication Sciences, University of
Vermont
- 1997–2002 Family Therapy Team, Department of Psychology, University of Vermont
(20 hours/month)
- 1998 Vermont Rural Autism Project (LEND Project), Department of
Communication Sciences, Burlington VT (20 hours/week)
- 1999 The May Center for Child Development, Chatham, MA (Summer training
institute: Behavioral Interventions for Children with Autism Spectrum
Disorders)
- 2000- 2003 Behavior Therapy and Psychotherapy Center, Dept. of Psychology,
University of Vermont (20 hrs/week)

HONORS:

- John Dewey Award for excellence in undergraduate research, 1990
- Member Phi Beta Kappa, 1996
- Graduate Student Travel Fellowship, 2003, University of Vermont Graduate College
- Travel Award Fellow, Society of Biological Psychiatry, May 2005

RESEARCH AND TRAINING SUPPORT:

Ongoing Grants:

Title: The Functional Neuroanatomy of Acute Nicotinic Modulation of Impulsivity in
Women

Sponsor: NIH/NIDA

Grant Number: 1R03DA023460

Dates: April 2008 – March 2009

Role: Principal Investigator

Title: The Effect of TC1734 on Behavioral Inhibition in Attention-Deficit/Hyperactivity
Disorder (ADHD)

Sponsor: Targacept Inc.

Grant Number: None (Investigator Initiated Grant)

Dates: May 2008 – December 2009

Role: Co-Principal Investigator

Ongoing Grants Continued:

Title: Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study

Sponsor: Lilly Research Laboratories

Dates: July 2008 – June 2010

Role: Co-Investigator

Title: Clinical Research Loan Repayment Program

Sponsor: National Institutes of Health

Dates: September 2004 –December 2007, September 2008 – December 2010

Role: Clinical Researcher Loan Repayment Recipient

Completed Grants

Title: Correlates of Impulsivity in Young Adults

Sponsor: University of Vermont College of Medicine

Dates: January 2006 – December 2008

Role: Principal Investigator

Title: An open-label, behavioral-treatment controlled evaluation of the effects of extended release methylphenidate (Ritalin LA) on the frequency of cytogenetic abnormalities in children 6-12 years of age with attention-deficit/hyperactivity disorder (ADHD)

Sponsor: Novartis Inc.

Dates: September 2006 – June 2009

Role: Principal Investigator

Title: Cholinergic Effects on Inhibition and Delay in ADHD

Sponsor: National Institute of Mental Health

Grant Number: 1-RO3 MH073573-01A1

Dates: September 2005 –October 2007

Role: Principal Investigator

Title: Cholinergic Involvement in ADHD and Substance Abuse

Sponsor: National Institute of Mental Health/National Institute on Drug Abuse

Grant Number: 1-R21 MH069670-01

Dates: December 2003 – December 2006

Role: Co-Investigator

Title: The Effects of Acute Nicotine Administration on Motor Performance in Attention-Deficit/Hyperactivity Disorder (ADHD)

Sponsor: Fletcher Allen Health Care

Dates: October 2004 – December 2006

Role: Principal Investigator

Completed Grants Continued

Title: The Effects of Ultra Low-Dose Mecamylamine on Behavioral Inhibition in Attention-Deficit/Hyperactivity Disorder

Sponsor: Targacept Inc.

Dates: July 2003 – July 2005

Role: Co-Investigator

Title: The Effects of Acute Nicotine Administration on Behavioral Inhibition in Adolescents Diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)

Sponsor: Child and Adolescent Psychology Training and Research Inc.

Dates: September 1998 – December 1999

Role: Principal Investigator

PUBLICATIONS:

1. Newhouse, P., Potter, A., Corwin, J., Lenox, R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology, 108: 480-484, 1992
2. Newhouse, P.A., Potter, A., Lenox, R. The effects of nicotinic agents on human cognition: Possible therapeutic applications in Alzheimer's and Parkinson's diseases. Medicinal Chemistry Research, 2: 628-642, 1993
3. Newhouse, P.A., Potter, A., Corwin, J., Lenox, R. Modeling the nicotinic receptor loss in dementia using the nicotinic antagonist mecamylamine: effects on human cognitive functioning. Drug Development Research, 31: 71-79, 1994
4. Newhouse, P., Potter, A., Corwin, J., Lenox, R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology, 10: 93-107, 1994
5. Newhouse, P.A., Potter, A., Corwin, J., Lenox, R. The role of nicotinic systems in the cognitive disorder of Alzheimer's disease. In Giacobini, E., and Becker, R. (eds), Alzheimer's Disease: Therapeutic Strategies, Birkhäuser Boston, pp. 191-195, 1994
6. Newhouse, P.A., Potter, A., Piasecki, M., Geelmuyden, J., Corwin, J., Lenox, R. Nicotinic modulation of cognitive functioning in human. In Clark, P.B.S., Quik, M., Thurman, K., Adlkofer, F., (eds), The Effects of Nicotine on Biologic System (II), Birkhäuser Boston, pp. 345-351, 1995
7. Newhouse, P.A., Potter, A. The effects of nicotinic agents on cognition and behavior in Alzheimer's disease. Drug Development Research 38:278-289, 1996
8. Newhouse, P.A., Potter, A., Levin, E.D. Nicotinic systems and Alzheimer's disease: Implications for therapeutics. Drugs and Aging 11: 206-228, 1997

9. Potter, A., Corwin, J., Lang, J., Lenox, R., Newhouse, P.A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 improved learning in Alzheimer's disease Psychopharmacology, 142: 334-342, 1999
10. Newhouse, P.A., Potter, A., Kelton, M., Corwin, J. Nicotinic treatment of Alzheimer's disease Biological Psychiatry 49: 268-278, 2001
11. Potter, A., Newhouse P. (2001) Clinical Methodologies in the examination of nicotinic effects on cognition in *Nicotine and the Nervous System* . Levin, E. (ed) CRC Press, Boca Raton, pp 255-271
12. Newhouse P.A.,Singh A, Potter A . Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders. Current Topics in Medicinal Chemistry 4:267-282, 2004
13. Newhouse, P.A., Potter A., Singh A. Nicotinic Stimulation Effects on Cognitive Performance. Current Opinion in Pharmacology 4:36-46, 2004
14. Potter, A., Newhouse, P. The effects of acute nicotine administration on behavioral inhibition in adolescents with attention deficit-hyperactivity disorder (ADHD). Psychopharmacology 176: 182-194, 2004
15. Singh, A., Potter, A., Newhouse, P. Nicotinic acetylcholine receptor system and neuropsychiatric disorders. IDrugs (2004) 7(12): 1096-1103.
16. MacLeod, J., Potter, A., Simoni, M., Bucci, D. (2006). Nicotine administration enhances conditioned inhibition in rats. European Journal of Pharmacology, 551(1-3) 76-9.
17. Potter, A., Newhouse, P., Bucci, D. (2006). Central nicotinic cholinergic systems: A role in the cognitive dysfunction in Attention-Deficit/Hyperactivity Disorder? Behavioral Brain Research, 175(2) 201-11.
18. Potter, A and Newhouse P. (2008) Acute Nicotine Improves Cognitive Deficits in Young Adults with Attention-Deficit/Hyperactivity Disorder. Pharmacology, Biochemistry and Behavior, 88(4) 407-417.
19. Potter, AS., Ryan, K., Newhouse, PA (in press) Effects of Acute Ultra-Low Dose Mecamylamine on Cognition in Adult Attention-Deficit/Hyperactivity Disorder (ADHD). Human Psychopharmacology: Clinical and Experimental

ABSTRACTS:

1. Newhouse, P., Potter, A., Lenox, R. The effects of acute nicotinic blockade on cognitive functioning in normal humans. Presented at the 30th Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, December 1991
2. Newhouse, P., Potter, A., Corwin, J., Lenox, R. Blockade of nicotinic receptors impairs cognition. Presented at the 145th Annual Meeting of the American Psychiatric Association, Washington, D.C., May 1992
3. Newhouse, P.; Potter, A., Lenox, R. Effects of Nicotinic Agents on Cognitive Functioning. Presented at the 31st Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, December 1992
4. Newhouse, P., Potter, A., Corwin, J., Lenox, R. The effects of Mecamylamine in Alzheimer's disease and elderly normals. Presented at the 146th Annual Meeting of the American Psychiatric Association, San Francisco, CA., May 1993
5. Newhouse, P.A., Potter, A., Corwin, J., Lenox, R. The role of nicotinic systems in the cognitive disorder of Alzheimer's disease. Third International Springfield Symposium on Advances in Alzheimer Therapy, Springfield, IL, May 1994
6. Newhouse, P.A., Potter, A., Corwin, J., Lenox, R. Nicotine and nicotinic system effects on cognition. American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994
7. Newhouse, P.A.; Potter, A., Corwin, J.; Lenox R. Acute Cognitive Effects of Nicotine in Alzheimer's and Parkinson's diseases. American College of Neuropsychopharmacology Annual Meeting, San Juan PR. December 1995
8. Newhouse, P.A., Potter, A., Corwin, J. Acute administration of the cholinergic activator ABT-418 improves learning in Alzheimer's disease. Society of Research on Nicotine and Tobacco Annual Meeting, Washington, D.C., March 1996
9. Newhouse, P.A., Potter, A., Corwin, J., Lenox R. Acute administration of the nicotinic agonist ABT-418 improves learning in Alzheimer's disease. Annual Meeting, American Psychiatric Association, New York, NY, May 1996
10. Newhouse, P.A.; Potter, A. Effects of the novel nicotinic agonist ABT-418 in Alzheimer's disease. Annual Duke Symposium on Nicotinic Research, October 1998.
11. Potter, A., Newhouse, P.A.. Acute Nicotine Administration Improves Behavioral Inhibition in Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Annual Meeting, Biological Psychiatry, San Francisco, CA, May 2003
12. Potter, A., Lippiello, P., Newhouse, P.A. Acute Nicotine and Ultra Low-Dose Mecamylamine Effects on Cognition in Attention-Deficit/Hyperactivity Disorder

- (ADHD). Annual Meeting, Society for Neuroscience, San Diego, CA, October 2004
13. Potter, A., Newhouse, P.A. Cognitive Effects of Acute Nicotine and Ultra Low-Dose Mecamylamine in Attention-Deficit/Hyperactivity Disorder (ADHD). Annual Meeting, Society of Biological Psychiatry, Atlanta, GA, May 2005.
 14. Potter, A., Paulus, M., Corwin, J., Crone, E. Dysfunction of reward systems in psychopathology: Clinical and research implications. Annual Meeting, Society of Biological Psychiatry, Atlanta, GA, May 2005
 15. Potter A, Lippiello PM, Newhouse PA. Acute Nicotine and Ultra Low-Dose Mecamylamine Effects on Cognition in Attention-Deficit/Hyperactivity Disorder (ADHD) Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2005.
 16. Bucci, D.J., MacLeod, J.E., Simoni, M.K., Potter, A.S. Nicotine enhances the acquisition of a serial feature negative discrimination. Annual Meeting of the Pavlovian Society, Philadelphia, PA, December 2006
 17. Potter AS, Newhouse PA. Effects of acute nicotine on motor performance in Attention-Deficit/Hyperactivity Disorder (ADHD). Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX, February 2007
 18. Ryan KK, Newhouse PA, Potter AS. Nicotinic modulation of working memory in Attention-Deficit/Hyperactivity Disorder (ADHD): Implications for cigarette smoking. Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, TX., February 2007
 19. Potter AS, Ryan KK, Newhouse PA. The Effects of Acute Nicotine Administration on Working Memory and Motor Performance in Attention-Deficit/Hyperactivity. Annual Meeting, Society of Biological Psychiatry, San Diego, CA, May 2007
 20. Potter AS, Ryan KK, Newhouse PA. The Effect of Acute Nicotine on Psychophysiological Response to Reward and Extinction in ADHD. Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2007
 21. Ryan KK, Newhouse PA, Potter AS. Gender differences in the effect of acute nicotine on impulsivity in ADHD. Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2007
 22. Bucci DJ, Gould TJ, Levin ED, Newhouse PA & Potter AS. Translating nicotinic effects on cognition: From basic science to clinical populations and back again. Symposium, Society for Research on Nicotine and Tobacco, Portland, OR, February 2008.

23. Ryan KK & Potter AS. Self-reported impulsivity is related to behavioral inhibition: Implications for cigarette smoking. Society for Research on Nicotine and Tobacco, Portland, OR, February 2008.
24. Potter AS & Newhouse PA. Cognitive Effects of Acute Nicotine and Ultra Low-Dose Mecamylamine in Attention-Deficit/Hyperactivity Disorder (ADHD). Society of Biological Psychiatry, Washington, DC, March 2008.
25. Potter AS & Newhouse PA. Nicotine improves behavioral inhibition in young adults with ADHD but not healthy controls. Society for Neuroscience, Washington, DC, November 2008
26. Ryan KK & Potter AS. Risk Taking and Models of Impulsivity in ADHD. Society for Neuroscience, Washington, DC, November 2008
27. Newhouse PA, Potter AS, Bucci DJ. Recent Advances in Understanding the Role of Central Nicotinic Cholinergic systems in ADHD using Translational Models. American College of Neuropsychopharmacology, Scottsdale, AZ, December 2008.